Mild Cognitive Impairment
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
The main purpose of this study is to investigate the safety and efficacy of the study drug solanezumab in participants with prodromal Alzheimer's Disease (AD).
This trial stopped recruiting or enrolling participants prematurely and will not start again. We are no longer examining or treating participants. The trial may have been stopped for many reasons. You may contact Lilly for further information.
Your participation could last up to 28 months and include 29 visits to the study center.
Here you can find out a bit more about the requirements for volunteers who took part in this study
Participant must have cognitive impairment that is evaluated as prodromal Alzheimer's disease (AD) by the study investigator
Participant must not have had an MRI or CT of brain within the previous 2 years that would be inconsistent with a diagnosis of AD
Participant must not have received treatment with a stable dose of an achetylcholinesterase (AChEI) inhibitor or memantine for less than 4 months before entering the study